ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

被引：11
|
作者：
Oluwole, Olalekan O. [1 ]
Kenderian, Saad S. [2 ]
Shiraz, Parveen [3 ]
Karmali, Reem [4 ]
Reshef, Ran [5 ]
McCarthy, Philip L. [6 ]
Ghosh, Nilanjan [7 ]
Lazaryan, Aleksandr [8 ]
Filosto, Simone [9 ]
Poddar, Soumya [9 ]
Mao, Daqin [9 ]
Peng, Andrew [9 ]
Kilcoyne, Adrian [10 ]
Nahas, Myrna [9 ]
Neelapu, Sattva S. [11 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Mayo Clin, Div Hematol, Dept Med, Rochester, MN USA
[3] Stanford Univ, Dept Med, Sch Med, Div Blood & Marrow Transplantat & Cellular Therap, Stanford, CA 94305 USA
[4] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA
[5] Columbia Univ, Blood & Marrow Transplantat Program, New York, NY USA
[6] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[7] Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA
[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat & Cellular Immun, Tampa, FL USA
[9] Kite, Santa Monica, CA USA
[10] Humanigen Inc, Burlingame, CA USA
[11] MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-167688
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10318 / 10320
页数：3
相关论文
共 50 条
  • [1] ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel in Patients With Relapsed or Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 13 - 14
  • [2] ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)
    Kenderian, Saad S.
    Oluwole, Olalekan O.
    McCarthy, Philip L.
    Reshef, Ran
    Shiraz, Parveen
    Ahmed, Omar
    Le Gall, John
    Nahas, Myrna
    Tang, Lily
    Neelapu, Sattva S.
    BLOOD, 2020, 136
  • [3] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
    Koji Kato
    Shinichi Makita
    Hideki Goto
    Junya Kanda
    Nobuharu Fujii
    Kazuyuki Shimada
    Koichi Akashi
    Koji Izutsu
    Takanori Teshima
    Natsuko Fukuda
    Tokuhito Sumitani
    Hiroyuki Sumi
    Shinji Shimizu
    Yasuyuki Kakurai
    Kenji Yoshikawa
    Kensei Tobinai
    Noriko Usui
    Kiyohiko Hatake
    International Journal of Clinical Oncology, 2022, 27 : 213 - 223
  • [4] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
    Kato, Koji
    Makita, Shinichi
    Goto, Hideki
    Kanda, Junya
    Fujii, Nobuharu
    Shimada, Kazuyuki
    Akashi, Koichi
    Izutsu, Koji
    Teshima, Takanori
    Fukuda, Natsuko
    Sumitani, Tokuhito
    Sumi, Hiroyuki
    Shimizu, Shinji
    Kakurai, Yasuyuki
    Yoshikawa, Kenji
    Tobinai, Kensei
    Usui, Noriko
    Hatake, Kiyohiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 213 - 223
  • [5] Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 16 - 18
  • [6] Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
    Neelapu, Sattva S.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Deol, Abhinav
    Miklos, David B.
    Bartlett, Nancy L.
    Braunschweig, Ira
    Jiang, Yizhou
    Kim, Jenny J.
    Zheng, Lianqing
    Rossi, John M.
    Locke, Frederick L.
    BLOOD, 2020, 135 (23) : 2106 - 2109
  • [7] Outcomes by Prior Lines of Therapy in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 11 - 13
  • [8] Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
    Nath, Karthik
    Wudhikarn, Kitsada
    Alarcon Tomas, Ana
    Perales, Miguel-Angel
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (01) : 5 - 15
  • [9] Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
    Grana, Allison
    Gut, Natalia
    Williams, Kiersten
    Maakaron, Joseph
    Porter, Kyle
    William, Basem M.
    Vasu, Sumithira
    Penza, Sam
    Brammer, Jonathan E.
    Saad, Ayman
    Puto, Marcin
    Jaglowski, Samantha M.
    Roddy, Julianna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (04): : 238 - 245
  • [10] Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
    Jallouk, Andrew P.
    Gouni, Sushanth
    Westin, Jason
    Feng, Lei
    Mistry, Haleigh
    Steiner, Raphael E.
    James, Jinsu
    Noorani, Mansoor
    Horowitz, Sandra
    Puebla-Osorio, Nahum
    Fayad, Luis E.
    Iyer, Swaminathan P.
    Hawkins, Misha
    Flowers, Christopher R.
    Ahmed, Sairah
    Nastoupil, Loretta J.
    Kebriaei, Partow
    Shpall, Elizabeth J.
    Neelapu, Sattva S.
    Nieto, Yago
    Strati, Paolo
    HAEMATOLOGICA, 2023, 108 (04) : 1163 - 1167
12345